Related Experiment Video
Updated: Mar 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renin-angiotensin system blockade: Finerenone
Luis M Ruilope1, Juan Tamargo2
1Instituto de Investigación imas, Madrid, Spain; Unidad de Hipertensión, Hospital 12 de Octubre, Departamento de Medicina Preventiva y Salud Publica, Universidad Autónoma, Avda de Cordoba s/n, 28041 Madrid, Spain; Escuela de Estudios Postdoctorales e Investigación, Universidad Europea de Madrid, Madrid, Spain.
Abstract:
Finerenone is a novel selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of finerenone were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone and phase II studies in finerenone in patients with heart failure, type-2 diabetes mellitus and/or chronic kidney disease are encouraging as the drug is effective and safe in patients on renin-angiotensin system inhibitors (significant reduction in albuminuria and a low rate of hyperkalemia), but the primary end points were "soft" end points (serum potassium, estimated glomerular filtration rate, albuminuria, N-terminal prohormone B-type natriuretic peptide levels). Thus, further, large-scale, long-term phase III trials are needed to confirm whether the greater affinity and selectivity is translated into improved clinical outcomes.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics
Hormonal Regulation

